Thrombotic thrombocytopenic purpura in metastatic carcinoma of the breast

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 23, Issue 1, 2000, Pages 74-77

  Von Bubnoff III, Nikolas ^a   Sandherr, Michael ^a   Schneller, Folker ^a   Peschel, Christian ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Coagulopathy; Metastatic carcinoma; Microangiopathic hemolytic anemia; Plasma exchange therapy; Thrombotic thrombocytopenic purpura

Indexed keywords

EPIRUBICIN; FUROSEMIDE; HEPARIN; METHYLPREDNISOLONE; NAVELBINE; SPIRONOLACTONE;

ADULT; ARTICLE; BREAST ADENOCARCINOMA; CANCER CHEMOTHERAPY; CASE REPORT; DISEASE ASSOCIATION; FEMALE; HEPARINIZATION; HUMAN; METASTASIS; PLASMAPHERESIS; RELAPSE; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME;

ADENOCARCINOMA; BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; PURPURA, THROMBOTIC THROMBOCYTOPENIC;

EID: 0034087751     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-200002000-00021     Document Type: Article

References (19)

1. Kwaan HC. Clinicopathologic features of thrombotic thrombocytopenic purpura. Semin Hematol 1987;24:71-81.
2. Moake JL. Hemolytic-uremic syndrome: basic science. Lancet 1994;343:393-7.
3. Moake JL, Chow TW. Thrombotic thrombocytopenic purpura: understanding a disease no longer rare. Am J Med Sci 1998;316: 105-19.
4. Rock GA, Shumak KH, Buskard NA, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med 1991;325:393-7.
5. Bell WR, Braine HG, Ness PM, Kickler TS. Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: clinical experience of 108 patients. N Engl J Med 1991; 325:398-403.
6. Moake JL. Studies on the pathophysiology of thrombotic thrombocytopenic purpura. Semin Hematol 1997;34:83-9.
7. Tsai HM. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 1996;87:4235-44.
8. Furlan M, Robles R, Lamie B. Partial purification and characterisation of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 1996; 87:4223-34.
9. Furlan M, Robles R, Galbusera M, et al. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998;339:1578-84.
10. Byrnes JJ, Khurana M. Treatment of thrombotic thrombocytopenic purpura with plasma. N Engl J Med 1977;297:1386-9.
11. Tsai H-M, Lian EC-Y. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998;339:1585-94.
12. Antman K, Skarin A, Mayer R. Microangiopathic hemolytic anemia and cancer: a review. Medicine 1979;58:377-84.
13. Lesesne JB, Rothschild N, Erickson B, et al. Cancer-associated hemolytic-uremic syndrome: analysis of 85 cases from a national registry. J Clin Oncol 1989;6:781-9.
14. Kressel BR, Ryan KP, Duong AT, et al. Microangiopathic hemolytic anemia, thrombocytopenia, and renal failure in patients treated for adenocarcinoma. Cancer 1981;48:1738-45.
15. Lohrmann HP, Adam W, Heymer B, et al. Microangiopathic hemolytic anemia in metastatic carcinoma: report of eight cases. Ann Intern Med 1973;79:368-75.
16. Kwaan HC, Soff GA. Management of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Semin Hematol 1997;34:159-66.
17. Murgo A. Thrombotic microangiopathy in the cancer patient including those induced by chemotherapeutic agents. Semin Hematol 1987;24:161-77.
18. Bell WB. Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome relapse: frequency, pathogenesis, and meaning. Semin Hematol 1997;34:134-9.
19. Gordon LI, Kwaan HC. Cancer- and drug-associated thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Semin Hematol 1997;34:140-7.